|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
863 consecutive colorectal cancer patients treated at Helsinki University Central Hospital in 1983–2001 were collected with 752 scored successfully for CIP2A immunohistochemical expression from tumor tissue microarrays.
|
22310977 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
|
15342917 |
2004 |
|
Clear-cell metastatic renal cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Clear cell RCC showed an even higher-CIP2A expression level than papillary or chromophobe RCC did.
|
22075943 |
2011 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Helicobacter pylori enhances CIP2A expression and cell proliferation via JNK2/ATF2 signaling in human gastric cancer cells.
|
24398514 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CIP2A expression (mRNA and protein) was measured in three different sets of human mammary tumors and compared with clinicopathologic variables.
|
19671842 |
2009 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
KIAA1524: A novel MLL translocation partner in acute myeloid leukemia.
|
20943269 |
2011 |
|
Lip and Oral Cavity Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
CIP2A expression and localization in oral carcinoma and dysplasia.
|
21068540 |
2010 |
|
Oral Cavity Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CIP2A expression and localization in oral carcinoma and dysplasia.
|
21068540 |
2010 |
|
Malignant transformation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
CIP2A may play a significant role in oral malignant transformation and therefore, it may be a potential target for chemotherapy of OSCC.
|
21068540 |
2010 |
|
Rheumatoid Arthritis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CIP2A mRNA expression was higher in RA FLS compared with those in OA FLS, but did not reach statistical significance (P = 0.076).
|
21479604 |
2012 |
|
Malignant neoplasm of stomach
|
0.070 |
Biomarker
|
disease |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) is a recently described inhibitor of PP2A in breast and gastric cancer.
|
21490338 |
2011 |
|
Stomach Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) is a recently described inhibitor of PP2A in breast and gastric cancer.
|
21490338 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CIP2A is overexpressed in cervical cancer and promotes the malignant growth of cervical cancer cells.
|
21575984 |
2011 |
|
Malignant tumor of cervix
|
0.040 |
Biomarker
|
disease |
BEFREE |
CIP2A protein was detected in 52.8% of cervical cancer (n=72) and 12.5% of CIN III tissues (n=24) but not in normal (n=15), CIN I (n=21) or CIN II samples (n=25).
|
21575984 |
2011 |
|
Cervix carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
CIP2A protein was detected in 52.8% of cervical cancer (n=72) and 12.5% of CIN III tissues (n=24) but not in normal (n=15), CIN I (n=21) or CIN II samples (n=25).
|
21575984 |
2011 |
|
cervical cancer
|
0.040 |
Biomarker
|
disease |
BEFREE |
CIP2A protein was detected in 52.8% of cervical cancer (n=72) and 12.5% of CIN III tissues (n=24) but not in normal (n=15), CIN I (n=21) or CIN II samples (n=25).
|
21575984 |
2011 |
|
Carcinoma in situ of uterine cervix
|
0.010 |
Biomarker
|
disease |
BEFREE |
CIP2A protein was detected in 52.8% of cervical cancer (n=72) and 12.5% of CIN III tissues (n=24) but not in normal (n=15), CIN I (n=21) or CIN II samples (n=25).
|
21575984 |
2011 |
|
Cervical intraepithelial neoplasia grade 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
CIP2A protein was detected in 52.8% of cervical cancer (n=72) and 12.5% of CIN III tissues (n=24) but not in normal (n=15), CIN I (n=21) or CIN II samples (n=25).
|
21575984 |
2011 |
|
Cervical intraepithelial neoplasia grade 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
CIP2A protein was detected in 52.8% of cervical cancer (n=72) and 12.5% of CIN III tissues (n=24) but not in normal (n=15), CIN I (n=21) or CIN II samples (n=25).
|
21575984 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) is a human oncoprotein inhibiting PP2A in many human malignancies.
|
21655278 |
2011 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cancerous inhibitor of protein phosphatase 2A may be a novel target for prevention and treatment of RCC metastasis and recurrence.
|
22075943 |
2011 |
|
Malignant tumor of colon
|
0.060 |
Biomarker
|
disease |
BEFREE |
CIP2A was an independent prognostic factor in colon cancer after controlling for other clinical confounding factors, such as stage and lymphovascular invasion, particularly in stages III and IV (hazard ratio = 2.974, P < 0.001).
|
22328001 |
2012 |
|
Colon Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
CIP2A was an independent prognostic factor in colon cancer after controlling for other clinical confounding factors, such as stage and lymphovascular invasion, particularly in stages III and IV (hazard ratio = 2.974, P < 0.001).
|
22328001 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CIP2A was an independent prognostic factor in colon cancer after controlling for other clinical confounding factors, such as stage and lymphovascular invasion, particularly in stages III and IV (hazard ratio = 2.974, P < 0.001).
|
22328001 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is highly expressed in hepatocellular carcinoma (HCC) and promotes cell proliferation, cell invasion, and aggressive tumor behavior.
|
22847158 |
2012 |